Merrion Announces Filing of F1 for Initial Public Offering in the United States
DUBLIN, Ireland, and WILMINGTON, N.C., April 02, 2007 -- Merrion Pharmaceuticals Ltd today announced that it has filed a Registration Statement on Form F-1 with the US Securities & Exchange Commission in the United States relating to the proposed initial public offering of its ordinary shares in the form of American Depositary Shares and ordinary shares. Merrion plans to apply to list its American Depositary Shares on the Nadsaq Global Market, and its ordinary shares on the Irish Enterprise Exchange in Dublin, Ireland.
Punk, Ziegel & Company is the lead book-running manager, and Goodbody Stockbrokers and Stanford Group Company are acting as co-managers.
The proposed offering will be made only by means of a prospectus. When available, a written prospectus related to the offering may be obtained from Punk, Ziegel & Company, 520 Madison Avenue, New York, NY, 10022, Tel. 212-308- 9494, Facsimile 212-308-1466, Attention: Syndicate.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state.
About Merrion Pharmaceuticals Ltd
Established in 2004, Merrion Pharmaceuticals (www.merrionpharma.com) is a privately held international specialty pharmaceutical company, engaged in the development of improved oral dosage forms of drugs that have poor bioavailability, including injectable drugs, certain existing oral drugs and large molecule drug candidates. Merrion's drug delivery technologies increase bioavailability by improving absorption in the gastrointestinal, or GI, tract, thereby enhancing efficacy, reducing side effects and improving drug tolerability. Merrion's primary focus is on developing patentable improved oral therapeutics that can replace injectable drugs, thereby increasing physician and patient acceptance. Merrion holds more than 35 issued and in- process patents for the delivery of a variety of drugs and biologics based on their patented GIPET(TM) and GIRES(TM) drug delivery platforms. Merrion has operations in Wilmington, NC and Dublin, Ireland.
CONTACT: USA inquiries: Michelle Miller of Merrion Pharmaceuticals,+1-910-799-1847, ; or Europe inquiries: WallyYoung of Young Communications, +353 (0)1-668-0530, +353 (0)1-7247-1520, mmiller@merrionpharma.com youngcom@eircom.net